ARQ 197

Phase 2Completed
0 views this week 0 watching💤 Quiet
Interest: 35/100
35
Hype Score

Development Stage

Pre-clinical
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Gastric Cancer

Conditions

Gastric Cancer

Trial Timeline

Jun 1, 2010 → Aug 1, 2011

About ARQ 197

ARQ 197 is a phase 2 stage product being developed by Kyowa Kirin for Gastric Cancer. The current trial status is completed. This product is registered under clinical trial identifier NCT01152645. Target conditions include Gastric Cancer.

What happened to similar drugs?

5 of 20 similar drugs in Gastric Cancer were approved

Approved (5) Terminated (3) Active (13)
ApatinibTabletsJiangsu Hengrui MedicineApproved
ApatinibJiangsu Hengrui MedicineApproved
Esomeprazole SodiumAstraZenecaApproved
trastuzumab [Herceptin]RocheApproved

Hype Score Breakdown

Clinical
12
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (3)

NCT IDPhaseStatus
NCT01656265Phase 1Completed
NCT01580735Phase 2Completed
NCT01152645Phase 2Completed